Loading...
NPI 1295050110 · Boise, ID · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ali Torab Parhiz is a ophthalmology physician provider located in Boise, Idaho. This profile covers 27 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Ali Torab Parhiz |
| Address | 901 N Curtis Rd Ste 302 |
| City | Boise |
| State | ID |
| ZIP | 83706 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | April 3, 2010 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.3M |
| Medicaid | $7.8K |
Payer mix is heavily Medicare‑weighted: the provider reports $4.3M in total Medicare revenue versus $7.8K in total Medicaid revenue, making Medicaid an effectively negligible portion of overall billing and indicating this practice is functionally single‑payer (Medicare) at scale. The small absolute Medicaid dollar volume suggests limited participation or volume in state‑program care compared with the provider's Medicare activity.
Revenue concentration on Medicare is extremely high and concentrated in intravitreal anti‑VEGF biologics: the top three Medicare codes (J2777, J2778, J0178) account for 80.6% of Medicare revenue, driven by J2777 at $2M revenue (47.7% of Medicare revenue), J2778 at $759.5K (17.7%), and J0178 at $657K (15.3%). These codes reflect an anti‑VEGF injection program as the primary revenue engine, consistent with focused medical retina treatment (recurrent injections for retinal disease).
Medicaid billing is also concentrated in injections and diagnostic imaging: the provider’s top three Medicaid codes account for 100.0% of Medicaid revenue, with 67028 alone representing $7.2K (92.4% of Medicaid revenue) from 57 claims. This mirrors the Medicare pattern (injection‑centric services) but at a very small scale in the Medicaid population, and in‑state ranking data indicate limited Medicaid market presence.
The provider is a major national volumetric outlier on certain codes: J2777 ranks #50 of 2039 providers nationally (98th percentile) and is described as notably above typical national volume, indicating unusually high faricimab administration compared with peers. By contrast J2778 and J0178 sit at more typical national volumes (J2778 ranks #62 of 1208 providers, described as typical/unremarkable; J0178 ranks #1297 of 3204, described as typical/unremarkable), so the provider’s anti‑VEGF mix is skewed toward J2777 specifically.
Diagnostic imaging and office visit volume are also extreme outliers, supporting a high‑throughput retina clinic model: 92134 shows 3.9K claims and $108.4K revenue and ranks #152 of 26868 providers (99th percentile; labeled an extreme outlier), while 99214 has 1.2K claims and $101.7K revenue and ranks #7199 of 479517 providers (98th percentile; labeled an extreme outlier). High OCT imaging plus high E/M volume is consistent with frequent follow‑up visits and monitoring that accompany recurrent intravitreal injection programs.
The practice performs both injection and surgical vitreoretinal procedures at lower absolute volumes: 67028 appears on both Medicare (2.7K claims, $241.6K revenue, 5.6% of Medicare revenue, rank #132 of 4255, 97th percentile, notably above typical) and Medicaid (57 claims, $7.2K, 92.4% of Medicaid revenue), and there are additional surgical codes present (67042, 67041, 67108) with modest revenue. This mix suggests the provider offers office‑based injections plus some vitreoretinal surgical capacity rather than a purely clinic‑only or purely surgical practice.
Tenure and stability: the NPI was enumerated 2010-04-03 (~16 years ago), indicating an established practice with a long billing history. Combined with concentrated, repeatable services (injections, imaging, E/M) this tenure supports operational continuity and an entrenched referral/monitoring workflow.
Operational and financial concentration risk is material: because 80.6% of Medicare revenue is tied to three codes (the anti‑VEGF/J‑drug codes noted above), changes in utilization patterns, formulary preferences, or reimbursement for these specific drugs could materially affect total revenue. Given Medicaid revenue is only $7.8K, there is limited payer diversification to buffer such shifts, so payers and network analysts should monitor drug‑specific utilization trends and any policy changes affecting J2777/J2778/J0178 reimbursement.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
27 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 70,560 | $30 | $2M |
| J2778 | Injection, ranibizumab, 0.1 mg | 4,270 | $180 | $759.5K |
| J0178 | Injection, aflibercept, 1 mg | 990 | $670 | $657K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,720 | $90 | $241.6K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 500 | $220 | $108.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,870 | $30 | $108.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,200 | $90 | $101.7K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 410 | $110 | $46.6K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 250 | $160 | $38.5K |
| J3490 | Unclassified drugs | 20 | $1,560 | $36K |
Showing 1–10 of 27
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 27 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
27 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 9 | 20 | 670 | $690 | $541.7K |
| J2777 | 1 | 10 | 8,640 | $30 | $454.7K |
| J2778 | 2 | 10 | 1,190 | $180 | $352.5K |
| J3490 | 9 | 10 | 230 | $880 | $174.8K |
| Q5128 | 1 | 10 | 500 | $220 | $108.5K |
| J7312 | 3 | 10 | 640 | $160 | $80.5K |
| 67028 | 1 | 30 | 470 | $90 | $66.6K |
| 67041 | 4 | 10 | 20 | $1,170 | $22.2K |
| 67108 | 1 | 10 | 10 | $1,130 | $19.2K |
| J7999 | 3 | 20 | 200 | $70 | $18.9K |
Showing 1–10 of 27
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 60 | $130 | $7.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 70 | $10 | $590 |
How this provider's Medicaid billing volume and revenue compare to other Idaho providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Idaho median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 11 | 10 | 990 | $50 | $87.9K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 13 | 20 | 690 | $20 | $29.7K |
Other providers in the same ZIP code as Ali Torab Parhiz, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Safeway Inc | ID | Community/Retail Pharmacy | $76.1M | $330 |
| Albertsons LLC | ID | Community/Retail Pharmacy | $29M | $0 |
| American Drug Stores LLC | ID | Community/Retail Pharmacy | $27.3M | $0 |
| Vons Companies Inc | ID | Community/Retail Pharmacy | $12.7M | $0 |
| Nai Saturn Eastern LLC | ID | Community/Retail Pharmacy | $12.6M | $0 |
| Smiles 4 Kids | ID | Dentist | $0 | $9.6M |
| Acme Markets Inc | ID | Community/Retail Pharmacy | $9.5M | $0 |
| Randalls Food & Drugs LP | ID | Community/Retail Pharmacy | $6.7M | $0 |
| Shaws Supermarkets Inc | ID | Community/Retail Pharmacy | $5.5M | $0 |
| Saint Alphonsus Regional Medical Center Inc | ID | General Acute Care Hospital | $0 | $5.1M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.